While more and more treatments have come on the market in recent years for the treatment of patients with inflammatory bowel disease (IBD). Biologics have revolutionized care in this regard and the expectation is that in the coming years there will still be more than garner approval from the US Food and Drug Administration (FDA). But there still are areas of care that need improvement. Access remains an issue, particularly in rural areas and minority communities. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more